You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A device containing immobilized chelator to remove aluminum from TPN solutions

    SBC: ALKYMOS, INC            Topic: N/A

    DESCRIPTION (provided by applicant): A high percentage of the ~ 470,000 children born prematurely each year in the US require intravenous feeding after birth because they do not tolerate oral feeding. This is accomplished with a total parenteral nutrition (TPN) solution, which is prepared from component solutions: small and large volume parenterals (SVPs and LVPs). Aluminum (Al) is a common conta ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  2. A Bioactive Prosthetic Vascular Graft

    SBC: BIOSURFACES INC            Topic: N/A

    DESCRIPTION (provided by applicant): Over 60,000 prosthetic grafts, which are comprised of either polyethylene terephthalate (polyester) or expanded polytetrafluoroethylene (ePTFE), are implanted in the United States each year. Medium (6-8mm) and small (l t5mm) internal diameter (I.D.) prosthetic arterial grafts continue to have unacceptably high failure rates when used in the clinical setting. T ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  3. Use of hyaluronan for treatment of chemotherapy sequelae

    SBC: CASCADE LIFESCIENCES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Among the most undesirable sequelae of chemo- and radiotherapies for the treatment of cancer are bone marrow hypoplasia and pancytopenia. These can further lead to immunodeficiency, bleeding and hypoxia significantly i mpacting the morbidity of cancer patients. The discovery of growth factors that regulate hematopoietic stem cells (HSC) proliferation led to th ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  4. Computer-Delivered Interventions for Secondhand Smoke Exposure

    SBC: EMERALD CITY ENTERTAINMENT GROUP, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Close to 40% of US children are exposed to secondhand tobacco smoke (SHS) in homes and up to 50% in cars, compromising the health and lives of millions of children. More effective, inexpensive, and accessible interventi ons are needed that impact parents' and caregivers' willingness and ability to institute smoking restrictions. We propose the development of an ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  5. Detection of Non-Human Sialic Acid in Biotherapeutic Applications

    SBC: GCFREE, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): GcFree, Inc. is founded on recent discoveries and patents about a sialic acid called Neu5Gc, which is present in large amounts on the surface of cells of most animals, but not humans. Potentially immunogenic Neu5Gc from exogenous sources (e.g., animal- derived reagents used for making biotherapeutic products) are taken up by human cells and expressed on their ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  6. HCV Genotyping and Drug Resistance Testing by ESI/MS

    SBC: IBIS BIOSCIENCES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Persistent infections with hepatitis C virus (HCV) are a major public health concern in the United States today. While diagnostic tests exist to identify and quantify HCV infections, there is a great need for analytical methods that provide detailed information about the molecular nature of HCV infections. HCV infections are marked by considerable genetic dive ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  7. Human Monoclonal Antibodies from Immunized Patient Lymphocytes

    SBC: MABVAX THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This Phase I STTR application is to support the development of a panel of human monoclonal antibodies (HmAbs) against sLea (also known as CA 19.9), a ganglioside extensively expressed at the cell surface of colon cancer s but also the majority of breast cancers. sLea is highly susceptible as a target for lysis by antibody directed mechanisms and since sLea serv ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  8. Conductivity-weighted ultrasound for cancer detection

    SBC: MAGNETUS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Inadequate sensitivity and specificity of currently-used imaging methods for cancer screening of the breast motivates the development of new modalities capable of adding diagnostic information. EMAI (electromagnetic aco ustic imaging) is a novel imaging method which exploits tissue electrical conductivity and acoustic properties for the purposes of cancer detec ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  9. Ultra-Rare Circulating Tumor DNA Detection with PAP and Digital Bead Technologies

    SBC: MAXWELL SENSORS INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Diagnosis and prognosis of cancer have increasingly benefited from the use of molecular markers and molecular approaches. Accumulating lines of evidence have shown that there is tumor DNA circulating in the peripheral blood of patients with a variety of cancers. Multiple studies have shown that circulating DNA carries genetic and epigenetic alterations that a ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  10. Small Molecule Drug Therapy for Parkinson's Disease

    SBC: NEOCYTEX BIOPHARMA, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The total cost of caring for Parkinson's disease is about 25 billion per year in the United States. There is an urgent and unmet need for an effective treatment for the patients who have suffered debilitating loss of n eurons and motor function. Development of neuroregeneration therapy is an important goal because neurdegenerative diseases disable and kill mil ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government